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Epigenetics as biomarker for Alzheimer’s disease:
a new approach to prevention, diagnosis and treatment
Alzheimer’s disease (AD) is a neurodegenerative disorder that
represents 65-75% of all cases of dementia. Early stages
features are typically attributed to age (apathy, lack of
attention, loss of motivation…) and advanced stages to
impairments for learning and orientation, dyspraxia and
anosognosia.
However, the definitive diagnosis is only determined by the
presence of β-amyloid plaques (Aβ plaques) and neurofibrillary
tangles (NFT) in post-mortem brains.
Data comes from research on PubMed database: scientific
literature that includes published reviews and papers.
Selection of literature: by key words, journal and above all
publication date (from 2005 to 2015).
Key words: Alzheimer’s disease, AD, biomarkers, epigenetics,
DNA methylation, histone modifications and non-coding
RNA.
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Epigenetics regulates genic expression without changing the sequence of DNA nucleotides. Epigenetic signature is persistent (as it can be 
inherited through generations) but also dynamic (because it is influenced by environmental stimuli).
Epigenetic changes are involved in phenotypic diversity but also represent a potential risk to develop neurological diseases such as AD.
Three epigenetic mechanisms altered in AD
CONCLUSIONS REFERENCES
Addition of CH3 to 5’ of cytosine forming 5-mC.
This process usually occurs in CpG islands, mainly
found in the promoter part of some human genes.
DNMTs are the enzymes that carry out the
reaction using SAM.
Evidences in post-mortem AD brains and blood
samples of patients with clinical dementia that
correlates with AD:
HYPO HYPER
APP
 PS1
 BACE-1
 NF-KB
COX-2
 BDNF
CREB
NEP
Acetylation, methylation, phosphorylation,
ubiquitylation, sumoylation and other post-translational
histone tail modifications are responsible for the
condensation state of chromatin (euchromatin or
heterochromatin):
 Histone methylation is regulated by HMTs and HDMTs
activity along with SAM accessibility. Its influence on
transcription is site-dependent.
 Histone phosphorylation usually favors transcription.
 Histone acetylation is the most studied post-translational
modification and it generally increases transcription.
Evidences in mouse models of AD and cell lines:
• Above all, overactivity of HDAC2 in certain brain areas
But also…
• Cellular stress H3 hyperacetylation
• Oxidative stress  H3 hypoacetylation and H3Lysine9
hypermethylation
Histone tail modifications
MiRNAs (also known as microRNAs) participate in
post-translational regulation of genic expression
by RNA silencing. They interfere with mRNA to
destabilize it and either provoke its degradation or
avoid its translation.
 Each miRNA recognizes up to hundreds of
mRNAs.
 Each mRNA is controlled by lots of miRNAs.
Evidences in post-mortem AD brains and mouse
models of AD:
• miR-29
• miR-34
• miR-29NEP
APP
 PS1
 BACE-1
TREM-2
TAU
 transcription
 transcription
DNA methylation Non-coding RNA: miRNAs
Factors influencing AD development
• Physical exercise, 
consumption of 
antioxidants…
• GeneticAPO-E4, TREM2…
• Non-genetic age, diet, 
stress, hypertension, diabetes, 
smoking, metals, pesticides…
Risk factors 
for AD
Life
experiences
Gene-expression profile 
linked to memory 
formation or disease risk
Transmission of disease 
risk to the next 
generation?
• Alzheimer’s disease has a big prevalence in global population and no efficient treatment has been found so far.
• Whereas some genetic and environmental factors have been identified to be a risk to the progression of this
neurodegenerative disorder, further research is needed to find a way for prevention and early diagnose.
• DNA methylation and histone tail acetylation patterns, as well as miRNAs expression levels have been associated to
transcriptional up and down-regulation of certain genes involved in AD development, such as APP, PS1 and BACE-1.
• Research focuses on the identification of biomarkers based on variations of epigenetic mechanisms that can be found in AD
patients comparing to same-aged healthy subjects.
• Given that epigenetic alterations could be modified, epigenome studies seem to be a new and promising line for AD therapy.
Fig. 3. Non-coding RNAs  
are indicated in purple. 
Coding RNAs are 
indicated in green and 
they allow the synthesis of 
proteins. 
Adapted from Fischer, 2014
Fig 1. Nucleosome 
representation, formed by 
DNA wrapped around a 
histone octamer. The 
methylation is indicated in 
green. DNA methylation 
leads to reduction of gene 
transcription.
Adapted from Fischer, 2014
Fig 2. Nucleosome 
representation. Histone 
tail modifications are 
indicated in red and 
yellow.
Adapted from Fischer, 2014
 BACE-1
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Familial Spontaneous
Early-onset
(< 65 years old)
Late-onset
(> 65 years old)
3% – 5% cases of AD 95% cases of AD
Gene mutations
Genetic and environmental 
risk factors
Apart from Aβ plaques and NFT, features such as
neuroinflammation, gliosis, synaptic dysfunction 
and cell death can be found in AD patients
Abbreviation Complete name Function
DNMT DNA-methyltransferase DNA methylation
HMT & HDMT
Histone methyltransferase
Histone demethylase
Histone methylation
Histone demethylation
HAT & HDAC
Histone acetyltransferase
Histone deacetylase
Histone acetylation
Histone deacetylation
SAM S-adenosylmethionine CH3 donor
APP Amyloid precursor protein
Membrane protein involved 
in plaques production
PS1 Presenilin-1 Enzyme for APP cleavage
BACE-1 β-secretase Enzyme for APP cleavage
NF-КB Nuclear factor-КB Neuroinflammation
COX-2 cyclooxygenase-2 Neuroinflammation
NEP Neprilysin Enzyme for Aβ degradation
TREM-2
Triggering receptor expressed 
on myeloid cells-2
Transmembrane
receptor
TAU τ protein Microtubules stabilization
TIPS!
Epigenetic
signature
METHYLATION
